Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism.

Clinica chimica acta; international journal of clinical chemistry - 1 Aug 2016

Duan Linli, Zhang Nuofu, Yan Huang, Guo Yehui, Hong Cheng, Yang Xinyan, Su Xiaofen, Chen Rongchang, Zhou Ying, Zhong Nanshan, Liu Chunli

Abstract excerpt

RATIONALE: Pulmonary embolism (PE) is a life-threatening manifestation of venous thromboembolism. Rivaroxaban is an oral anticoagulant, which directly inhibits Factor Xa. The objective of the current study was, in comparison to the standard-therapy method, to investigate the potential of rivaroxaban to improve the treatment of patients with PE, and to reduce hemorrhage in the standard-therapy group through...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Genotype

Share to Pulmonary Embolism

Share to Venous Thrombosis

Share to Vitamin K

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 27155586
DOI: 10.1016/j.cca.2016.05.002

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism.PMID 27155586Read ↗

[A randomized controlled study of the VKORC1 and CYP2C9 genotypes in guiding warfarin therapy for pulmonary thromboembolism].Semantic proximity Read ↗

Progress in the research on venous thromboembolism.Semantic proximity Read ↗

[Companion Diagnostics for Thrombotic Disease].Semantic proximity Read ↗

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism (deep vein thrombosis and pulmonary embolism) in four European countriesSemantic proximity Read ↗

[Clinical and genetic analysis of pulmonary embolism induced by a novel gene mutation of the antithrombin Ⅲ gene].Semantic proximity Read ↗

Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants.Semantic proximity Read ↗

Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients.Semantic proximity Read ↗

An ADR pharmaceutical care for severe gastrointestinal bleeding of rivaroxaban in a patient with non-valvular atrial fibrillation based on TDM and genetic testingSemantic proximity Read ↗

Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients With Atrial Fibrillation: A Randomized Parallel Group Trial.Semantic proximity Read ↗

Role of factor V Leiden or G20210A prothrombin mutation in patients with symptomatic pulmonary embolism and deep vein thrombosis: a meta-analysis of the literature.Semantic proximity Read ↗

Mutant CYP3A4/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation.Semantic proximity Read ↗

A Pilot Randomized Study of Atorvastatin As Adjunct Therapy in Patients with Acute Venous ThromboembolismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.